Prenatal Paracetamol Linked to Ovarian Development Changes
A recent study suggests infant girls exposed to the drug in utero may have smaller ovaries and fewer follicles.
Updated on Sept. 20, 2026 in Pregnancy
Live Poll
Is now a good time to reconsider using over-the-counter pain medication during pregnancy?
A study of 302 infant girls has identified a potential link between prenatal paracetamol exposure and differences in female reproductive development, such as reduced uterine size and fewer ovarian follicles. Up to 65% of U.S. women report using paracetamol during pregnancy.
Why it matters
Understanding the potential effects of common over-the-counter medications on fetal development is a critical health consideration for expectant parents. The FDA recently issued a notice to physicians regarding acetaminophen use during pregnancy following reports on the drug's safety profile.
The study examined 302 infants at three months of age, with researchers tracking exposure in 685 women through bi-weekly reports and urine samples. While 65% of U.S. women use the drug, the long-term impacts of these findings are currently under investigation in planned future studies.
The players
Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.
Janssen
A pharmaceutical company that researches and develops medical treatments.
The details
Researchers tracked paracetamol usage throughout the participants' pregnancies by combining maternal self-reporting with periodic urine concentration measurements. When the infants reached three months of age, physical assessments were conducted to measure reproductive organ size and ovarian follicle counts. The results reflected patterns previously seen in animal models, indicating a potential physiological effect on female reproductive development in utero.
Timeline
2018: A Janssen epidemiologist first noted evidence of potential connections.
September 2025: Reports surfaced regarding private internal acknowledgments by Janssen.
September 22, 2025: The FDA issued a formal notice to physicians about acetaminophen use.
September 20, 2026: The study on infant reproductive development was published.
The Home Front
This research follows the pattern set by the FDA notice to physicians regarding acetaminophen use, which highlighted the need for caution during pregnancy. It signals a shift in how medical professionals and families must evaluate the safety of common over-the-counter medications.
Expectant parents should discuss all medication use, including over-the-counter pain relievers, with their healthcare provider to understand current safety recommendations. It is important to review any prenatal care plan during scheduled doctor visits to address questions about drug exposure.
The takeaway
While these findings suggest a potential link between medication and development, further research is required to confirm the clinical outcome. Families should consult their primary care physician or OB-GYN to review medication safety during pregnancy.
What happens next
Researchers expect to conduct larger studies with extended follow-up periods to determine the clinical relevance of these findings for infant health.
Further reading
You can find more guidance on prenatal health in our Pregnancy section.
Live Poll
Is now a good time to reconsider using over-the-counter pain medication during pregnancy?
